Medexus Pharmaceuticals Inc. (TSE:MDP) Given Average Rating of “Strong Buy” by Brokerages

Medexus Pharmaceuticals Inc. (TSE:MDP) has been given an average recommendation of “Strong Buy” by the six brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a buy recommendation and five have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is C$5.58.

Several analysts have recently commented on the company. Stifel Nicolaus increased their price objective on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research note on Wednesday, January 8th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd.

Medexus Pharmaceuticals Stock Down 6.5 %

TSE:MDP opened at C$4.60 on Tuesday. The stock has a market capitalization of C$112.84 million, a price-to-earnings ratio of 92.00 and a beta of 1.96. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The firm has a 50 day moving average of C$3.30 and a 200 day moving average of C$2.74.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.